Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Blueprint: Inventing the Future. Catalyzing STEAM Access. Closing the Gap.

The New Chemist’s Podcasting Group — The Path to KOLs: Accelerating First-in-Human in LATAM — Julio G. Martinez-Clark, CEO, bioaccess® w/ Chadwin Hanna, MD-PhD Student (UF) and David Ferguson (Host)

16 Sep 2025

Description

The New Chemist’s Podcasting Group — The Path to KOLs: Accelerating First-in-Human in LATAM — Julio G. Martinez-Clark, CEO, bioaccess® w/ Chadwin Hanna, MD-PhD Student (UF) and David Ferguson (Host)---On The Path to KOLs from The New Chemist’s Podcasting Group, hosts David Ferguson and Chadwin Hanna explore how Latin America is becoming a strategic engine for high-quality, cost-effective clinical research.Julio G. Martinez-Clark—Ambassador of IAOCR/GCSA Americas and CEO of bioaccess®—breaks down how aligning to global competence standards and smarter site activation can compress timelines for First-in-Human and Early Feasibility Studies without compromising quality. He shares lessons from pioneering trials, practical blueprints for building city-level clinical hubs, and pragmatic guidance for innovators entering LATAM markets. The conversation also touches on sustaining regional infrastructure, cross-border collaboration, and the mindset behind his long-running Global Trial Accelerators™ series.Guest: Julio G. Martinez-Clark, CEO, bioaccess®Hosts: David Ferguson, BS, MS, Pharm.D. Candidate; Chadwin Hanna, MD Candidate & PhD StudentPlease note: The views of this podcast reflect those of my guest(s) and I, and do not constitute medical advice, consultation and suggestions. Please see a board certified and state licensed medical professional.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.